In July 2016, Radius entered into a preclinical collaboration with Takeda Pharmaceutical to evaluate a combination of the former’s elacestrant with the latter’s investigational drug TAK-228 in Phase 2b development for treating breast, endometrial, and renal cancer with the goal of potentially exploring such a combination in a clinical study.
In January 2016, Radius entered into a worldwide clinical collaboration with Novartis to evaluate the safety and efficacy of combining the former’s elacestrant with the latter’s ribociclib.
Notably, Radius Health makes up ~1.5% of the SPDR S&P Biotech ETF’s (XBI) total portfolio holdings.
In the next part of the series, we’ll take a look some of the key licensing agreements entered into by Radius Health.
View more information: https://marketrealist.com/2018/01/strong-pipeline-drugs-bodes-well-radius-health/